What Eli Lilly's move to cut prices on obesity drug Zepbound means for investors
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Zepbound
since
auto-detected in 21 stories
5 days ago
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
found
The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.
15 days ago
Eli Lilly hits $1 trillion market value, a first for a health-care company
The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
37 days ago
Eli Lilly and Merck’s blockbuster drug sales power earnings ⊕⊕
found
a story from Financial Times ✅ › Financial Times
Pharma groups boost financial outlooks as revenues from flagship medicines like Zepbound and Keytruda leap
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
found
a story from CNBC ⚠️ › World News
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.
38 days ago
Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
Starting in mid-November, cash-paying patients can purchase Zepbound vials at discounts of 50% or more through the retailer's locations or via home delivery.
85 days ago
Weight-loss drug boom has reached apparel store rack as America resizes
As more Americans use GLP-1 weight-loss drugs such as Ozempic, Zepbound, Wegovy and Mounjaro, the clothing industry rack is being resized, in surprising ways.
3 months ago
Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.
7 months ago
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro.